SSRI augmentation of antipsychotic alters expression of @entity1246 (A) receptor and related genes in PMC of @entity161 XXXX .

@entity1 @entity7601 @entity1246 @entity3755 @entity161 @entity2252
Clinical studies have shown that negative symptoms of @entity161 unresponsive to antipsychotic given alone can improve after augmentation with SSRI antidepressant. Laboratory investigations into the mechanism of this synergism showed that co-administration of SSRI and antipsychotic produces changes in @entity1246 (A) receptor and related systems, which differ from the effects of each drug alone. To examine the clinical relevance of these findings, the current study examined the effects of SSRI augmentation treatment on @entity1246 (A) receptor and related systems in @entity161 @entity1 . @entity161 @entity1 with high levels of negative symptoms unresponsive to antipsychotic treatment received add-on @entity3755 (100 mg/d). Blood was taken before and 1, 3 and 6 wk after adding @entity3755 and peripheral mononuclear cells (PMC) isolated. RNA encoding for @entity1246 (A)b3, @entity7601 , and 5-HT7 receptors, PKCb2, and @entity2252 ( @entity2252 ) was assayed with real-time RT-PCR. Plasma @entity2252 protein was assayed using ELISA. Clinical symptoms were assessed with validated rating scales. We found significant increase in mRNA encoding for @entity1246 (A)b3 and 5- @entity7601 , 5-HT7 receptors and @entity2252 and a reduction in PKCb2 mRNA. Plasma @entity2252 protein concentrations were increased. There were significant correlations among the genes. Clinical symptoms improved significantly. mRNA expression of PKCb2, @entity7601 and 5-HT7 showed significant associations with clinical symptoms. Combined SSRI+antipsychotic treatment is associated with changes in @entity1246 (A) receptor and in related signalling systems in @entity1 . These changes may be part of the mechanism of clinically effective drug action and may prove to be biomarkers of pharmacological response.
